We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
We’re responsible for regulating environmental and decommissioning activity for offshore oil and gas operations, including carbon capture and storage operations, on the UK continental shelf. OPRED is part of the Department for Energy Security and Net Zero .
Following the exit of Remploy Employment Services to the private sector, the Disabled People’s Employment Corporation manages its residual assets and liabilities.
The CMA investigated the anticipated acquisition by Theramex HQ UK Limited of the European Rights to Viatris’ Femoston and Duphaston Products.
We’re a collaborative research and development programme between the Environment Agency, Defra, Welsh Government and Natural Resources Wales. FCERM R&D Programme is part of the Department for Environment, Food & Rural Affairs , the Environment Agency , the Welsh Government...
Form REMO 10: Annex B - Application for enforcement of a decision made or recognised in the requested state.
Form REMO 11: Annex C - Application for establishment of a decision.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
List of Field Safety Notices from 21 to 25 October 2024.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).